Chromosome 3q29 Microduplication Syndrome — Comprehensive Disease Characterization

MONDO: MONDO:0012761 · Category: Chromosomal (genomic copy-number) disorder Report basis: Aggregated primary literature (case series, cohorts, reviews). No individual EHR data used. Date: 2026-09-03

Evidence note. This is a rare disorder described almost entirely through case reports and small cohorts. The largest single cohort to date is 46 patients (38421086). Frequencies below are indicative, not population-validated, and most mechanistic claims are inferred from gene content and from the better-studied reciprocal 3q29 deletion. Statements are flagged where they derive from the deletion rather than the duplication.

1. Disease Information

Overview. Chromosome 3q29 microduplication syndrome is a rare genomic disorder caused by a recurrent copy-number gain of ~1.6 Mb at chromosome band 3q29 (hg19 chr3:~195,700,000–197,350,000). It is the reciprocal of the better-characterized 3q29 microdeletion syndrome. The clinical picture is a variable, generally mild neurodevelopmental disorder: developmental/speech delay, learning disability or mild–moderate intellectual disability, and a range of accessory features (dysmorphism, ocular and cardiac anomalies, micro- or macrocephaly, obesity). Many carriers are only mildly affected and the duplication is often inherited from a similarly mild parent, so it behaves partly as a susceptibility factor rather than a fully penetrant syndrome (38421086 33039685 39739615).

Key identifiers. - MONDO: MONDO:0012761 - OMIM: 611936 (Chromosome 3q29 microduplication syndrome) - Orphanet: ORPHA:284169 (3q29 microduplication syndrome) - ICD-11: LD44 (chromosomal duplication category); ICD-10: Q92.3 (partial trisomy) - Reciprocal disorder: 3q29 microdeletion syndrome — OMIM 609425, Orphanet ORPHA:66634

Synonyms / alternative names: 3q29 duplication syndrome; 3q29 microduplication; trisomy 3q29; dup(3)(q29); 3q29 microduplication syndrome (reciprocal to 3q29 deletion).

Information source type: Disease-level aggregated resources plus published individual case reports; not derived from a single EHR system. A patient registry exists for the reciprocal deletion (3q29deletion.org, 37691301).

2. Etiology

Primary cause — genetic (structural). A recurrent interstitial duplication of ~1.6 Mb at 3q29 containing ~21 protein-coding genes (37165454). Reported duplications range from ~448 kb to ~2.3 Mb, classically spanning TFRC → BDH1 (29501613). Origin is non-allelic homologous recombination (NAHR) between flanking segmental duplications (low-copy repeats): in 89% (16/18) of probands breakpoints fell within paralogous 20-kbp segments inside the 3q29 SDs (37165454).

Genetic risk factors. - The recurrent CNV itself is the causal lesion. - Second-hit CNVs / additional variants act as risk/modifier factors and were frequent in cohorts (33039685); additional contributory genetic findings were present in 11/46 patients (38421086). - Local segmental-duplication architecture and haplotype diversity at 3q29 modulate NAHR risk (37165454).

Environmental risk factors: None established. No toxin, infectious, dietary, or occupational exposure is implicated in causing the CNV. Parental age effects are not established for this locus.

Protective factors: None specifically identified. Reduced penetrance implies protective genetic-background/modifier effects exist but are uncharacterized.

Gene–environment interactions: No specific GxE interaction documented. Variable expressivity is currently best explained by genetic modifiers / second-hit variants (oligogenic model), not by environment (33039685 38421086).

3. Phenotypes

Phenotype frequencies are approximate (small cohorts, ascertainment bias toward NDD). Duplication features are consistently less frequent and milder than in the reciprocal deletion (39739615).

• Phenotype characteristics: onset predominantly congenital-to-childhood; a notable late-onset (age 34) presentation with progressive cortical atrophy and recurrent mucosal infections has been reported (32874693). Severity is variable/mild; course generally stable (developmental), though brain-atrophy and epilepsy subsets may progress.
• Quality-of-life impact: driven mainly by cognitive/learning and speech impairment affecting education and daily functioning; cardiac/ocular anomalies may need intervention. No syndrome-specific EQ-5D/SF-36 data published for the duplication.

Core spectrum quote: "clinical features that include intellectual disability, language delay, epilepsy, structural brain anomalies, micro/macrocephaly, generalized obesity, ocular abnormalities, distinctive facial features, cleft palate, and musculoskeletal anomalies" (33039685).

Psychiatric distinction (important). Large schizophrenia case-control CNV studies associate the 3q29 deletion — not the duplication — with schizophrenia (24776740 22130109). The duplication is instead a recurrent susceptibility locus for autism spectrum disorder and developmental delay (22900207 39080272), with schizophrenia and generalized anxiety being phenotypes unique to deletion carriers (39739615). Counseling should reflect this dosage-direction asymmetry.

4. Genetic / Molecular Information

Causal lesion: recurrent 3q29 duplication (dosage gain), not a point mutation. Variant class: structural — copy-number gain (tandem/interstitial duplication). ACMG/AMP CNV classification: recurrent 1.6-Mb 3q29 duplication is generally VUS to likely pathogenic / pathogenic with reduced penetrance depending on inheritance and second hits; many are inherited from unaffected/mildly affected parents (38421086).

Genes in the recurrent interval (~21 protein-coding), key candidates: - DLG1 (HGNC:2900; SAP97) — synaptic MAGUK scaffolding protein; strongest candidate (29501613 24838842). - BDH1 (HGNC:1027) — mitochondrial 3-hydroxybutyrate dehydrogenase (ketone-body/energy metabolism); smallest single-gene critical region defined (39739615 29501613). - PAK2 (HGNC:8591) — p21-activated kinase; cytoskeletal/synaptic signaling (24838842). - FBXO45 (HGNC:29148) — synaptic ubiquitin-ligase adaptor, neuronal development (24838842). Full verified gene inventory (Ensembl GRCh37, chr3:195,700,000–197,350,000; 22 protein-coding genes, this analysis): BDH1, CEP19, DLG1, FBXO45, MFI2/MELTF, NCBP2, NRROS/LRRC33, PAK2, PCYT1A, PIGX, PIGZ, RNF168, SENP5, SLC51A/OSTA, SMCO1, TCTEX1D2, TFRC, TM4SF19, UBXN7, WDR53, ZDHHC19 (+1 putative transcript). This matches the literature "~21 genes" (37165454).

Contiguous-gene / dosage-pleiotropy links (candidate): beyond the neurodevelopmental core (DLG1, PAK2, FBXO45, BDH1), the interval carries genes with independent Mendelian disease relevance that plausibly contribute to the pleiotropic phenotype: CEP19 (recessive morbid obesity / ciliopathy → obesity), PCYT1A (retinal dystrophy with spondylometaphyseal dysplasia → ocular anomalies), RNF168 (RIDDLE-syndrome DNA-damage response → immune/radiosensitivity), TFRC (transferrin receptor; combined immunodeficiency → recurrent infections). These are hypothesized dosage contributors, not proven for the duplication.

Minimal critical region: progressively refined from DLG1+BDH1 (448 kb; 29501613) to BDH1 alone (single-gene duplications associated with ASD, heart defects, biliary tract dysfunction, obesity; 39739615).

Functional consequence: presumed gain-of-dosage (increased gene expression) of dosage-sensitive synaptic/metabolic genes; not loss-of-function.

Allele frequency: rare; the recurrent CNV is essentially absent/very rare in gnomAD-SV controls and enriched in NDD cohorts (~1:5000 among NDD patients; 39739615).

Somatic vs germline: germline; both de novo and inherited (most inherited; 38421086). Post-zygotic occurrence documented as a discordant CNV in monozygotic twins with psychosis (39080272).

Modifier genes / epigenetics: second-hit CNVs modify severity (33039685); no locus-specific methylation/histone signature (episignature) is established for the duplication. Chromosomal abnormality: dup(3)(q29), submicroscopic — karyotype normal, detected by microarray.

5. Environmental Information

No environmental, lifestyle, or infectious agent is known to cause or trigger 3q29 microduplication syndrome. It is a constitutional genomic disorder. (Obesity within the phenotype may be modulated by diet/lifestyle as in the general population, but this is not disease-specific.) Infectious agents: not applicable.

6. Mechanism / Pathophysiology

Causal chain (initiating lesion → clinical manifestation):

1. Segmental duplications flanking 3q29 provide high sequence identity that predisposes to misalignment during meiosis (37165454).
2. Misalignment leads to non-allelic homologous recombination (NAHR) between paralogous ~20-kbp SD segments (37165454).
3. NAHR results in a recurrent ~1.6-Mb duplication (3 copies) of ~21 genes, transmitted in the germline.
4. Extra gene copies lead to increased dosage/expression of dosage-sensitive genes — notably DLG1, BDH1, PAK2, FBXO45 (inferred; 29501613 24838842).
5. Elevated DLG1/PAK2/FBXO45 dosage is inferred to perturb synapse assembly, glutamatergic scaffolding and neuronal cytoskeletal signaling (inferred from gene function; 24838842).
6. Elevated BDH1 dosage is inferred to alter ketone-body/mitochondrial energy metabolism, potentially affecting neuronal and biliary function (inferred; 39739615).
7. Synaptic + metabolic perturbation leads to altered neurodevelopment → developmental/speech delay, learning disability, variable ID, seizures, brain structural anomalies (33039685 29501613).
8. Branch: presence of a second-hit variant/CNV shifts the outcome toward more severe/syndromic disease (e.g., cerebral palsy, severe ID); its absence results in the common mild phenotype (33039685 38421086).
9. Reduced penetrance: in a permissive genetic background the dosage gain may produce no or minimal clinical effect (inherited-from-unaffected-parent scenario; 38421086).

Molecular pathways (candidate): glutamatergic synaptic scaffolding via DLG1/PSD-95 family (MAGUK); PAK2-mediated Rho-GTPase/cytoskeletal signaling; ketone-body metabolism via BDH1. Cellular processes: synapse organization, dendritic/spine development, neuronal migration (heterotopia reported, 29501613). Metabolic changes: possible ketone/energy-metabolism shift via BDH1 (interconverts acetoacetate ↔ D-3-hydroxybutyrate; CHEBI:17968 (R)-3-hydroxybutyrate, CHEBI:13705 acetoacetate), and biliary tract dysfunction (39739615); SLC51A/OSTA in the interval is a bile-acid transporter, offering a candidate link to the reported biliary phenotype. Immune involvement: recurrent infections in isolated cases (32874693) — not a core feature.

Model-organism support: direct duplication models are lacking. Deletion Df/+ mice show neurodevelopmental/behavioral abnormalities and reduced paraventricular oxytocin neurons, with social deficits rescued by oxytocin (35346312) — informative for the locus but reflecting loss, not gain, of dosage.

Suggested ontology terms: GO:0050808 (synapse organization), GO:0007268 (chemical synaptic transmission), GO:0007612/GO:0007611 (learning/memory), GO:0046951 (ketone body biosynthesis); CL:0000540 (neuron), CL:0000679 (glutamatergic neuron).

7. Anatomical Structures Affected

• Primary organ/system: central nervous system (UBERON:0001017) — brain (UBERON:0000955); cerebral cortex, lateral ventricles (periventricular heterotopia, 29501613), cortical atrophy (32874693).
• Secondary organ involvement: eye (UBERON:0000970) — ocular anomalies; heart (UBERON:0000948) — congenital heart defects; craniofacial skeleton — dysmorphism, cleft palate (UBERON:0001716 secondary palate); musculoskeletal system; teeth; biliary tract (case-level, 39739615); adipose/metabolic (obesity).
• Body systems: nervous, cardiovascular, ocular/visual, musculoskeletal, craniofacial, endocrine/metabolic.
• Cell/tissue level: neurons and synapses (nervous tissue) are the principal targets.
• Subcellular: postsynaptic density/synapse (GO:0014069), mitochondria (GO:0005739, via BDH1), nucleus.
• Lateralization: generally bilateral/symmetric; the reported heterotopia was unilateral (right lateral ventricle, 29501613).

8. Temporal Development

• Onset: congenital to early childhood; developmental delay usually recognized in infancy/toddlerhood. A late-onset adult presentation (34 y) is documented (32874693). Onset pattern: insidious/chronic (developmental).
• Progression: developmental features are generally stable over time; most carriers are non-progressive. Subsets show progressive features (cortical atrophy, epilepsy) (32874693). Duration: lifelong.
• Course pattern: static/chronic; not relapsing-remitting.
• Critical periods: prenatal/early-childhood neurodevelopment is the key window; several diagnoses were made prenatally by microarray (33039685), enabling early developmental intervention.

9. Inheritance and Population

• Epidemiology: rare; estimated ~1:5000 among patients with a neurodevelopmental phenotype (39739615). General-population prevalence is not firmly established; only ~60+ patients are described in the literature (16 early cases + 11 [PMID 33039685] + 46-patient cohort [PMID 38421086] + others).
• Inheritance pattern: autosomal, dominant with reduced penetrance and variable expressivity; most cases inherited from a mildly affected/unaffected parent, some de novo (38421086).
• Penetrance: incomplete/reduced (39739615). Expressivity: highly variable (32874693).
• Anticipation: not established. Germline/post-zygotic mosaicism: post-zygotic origin documented in an MZ-twin pair discordant for psychosis (39080272). Founder effects/consanguinity: not relevant (recurrent NAHR event, not a founder mutation). Carrier frequency: not defined.
• Population demographics: no strong ethnic predilection; cohorts from Europe (France, Romania, Italy), North America, China. Sex ratio: roughly balanced/slight male excess in NDD cohorts (~56–62% male in related 3q29 series, 37691301 35297118). Age distribution: predominantly children at ascertainment.

10. Diagnostics

• First-line test: chromosomal microarray analysis (CMA / aCGH / SNP-array) — the diagnostic gold standard; detects the submicroscopic ~1.6-Mb gain (33039685 32874693). Karyotype is normal (lesion below cytogenetic resolution).
• Confirmation/segregation: qPCR and FISH; parental testing to assess inheritance (39739615).
• Sequencing: WES/WGS recommended when presentation is severe or syndromic, to detect modifying second-hit variants (38421086). Long-read/optical mapping resolves complex SD architecture and breakpoints (research; 37165454).
• Prenatal: CMA on chorionic villus/amniocentesis samples — several 3q29 duplications identified prenatally (33039685).
• Adjunct workup by phenotype: brain MRI (heterotopia, atrophy; 29501613 32874693), echocardiography (CHD), ophthalmologic exam, developmental/cognitive assessment.
• Biomarkers: no specific molecular biomarker; diagnosis is genomic.
• Differential diagnosis: other recurrent NDD-associated CNVs (16p11.2, 22q11.2, 1q21.1), 3q29 deletion syndrome, and overlapping trisomy 3q / adjacent CNVs (e.g., 1q43q44 overlap, 30263904; OAVS-associated proximal 3q29 dup, 25735547). Co-occurring monogenic disease can confound (e.g., AMeD/ADH5-ALDH2, 41039406).
• Screening: not part of newborn screening; cascade testing of relatives is appropriate given frequent inheritance.

11. Outcome / Prognosis

• Survival/mortality: the syndrome is not intrinsically life-limiting; no reduced life expectancy documented for isolated duplications. Mortality risk depends on associated anomalies (e.g., severe congenital heart disease).
• Morbidity/function: dominated by learning disability, speech/language impairment and variable ID; global adaptive-function deficits are well documented in the reciprocal deletion (37740553) and, more mildly, expected here. Most isolated-duplication patients have mild NDD (38421086).
• Complications: epilepsy, structural brain anomalies, cardiac and ocular disease, obesity, musculoskeletal issues; psychiatric comorbidity possible but less than in the deletion (schizophrenia/GAD were unique to deletion carriers, 39739615).
• Recovery/course: developmental features are stable/chronic; early intervention (speech/OT/PT, special education) improves functional outcome.
• Prognostic factors: presence of a second-hit variant and additional structural anomalies predict a more severe outcome (33039685 38421086); isolated duplication predicts milder outcome.

12. Treatment

No disease-specific or curative therapy exists; management is symptomatic, multidisciplinary and supportive.

• Developmental/behavioral: early intervention — speech therapy, occupational therapy, physical therapy, special education; behavioral support for ASD/ADHD features (NCIT: Rehabilitation Therapy).
• Neurologic: standard antiseizure medication for epilepsy (NCIT: Anticonvulsant Agent).
• Psychiatric: treat comorbid ADHD/anxiety/psychosis per standard guidelines if present (more relevant to the reciprocal deletion).
• Cardiac: surgical/interventional correction of congenital heart defects as indicated (e.g., valvuloplasty) (NCIT: Cardiac Surgery); reciprocal-deletion literature includes balloon valvuloplasty for pulmonary stenosis (36305444).
• Ophthalmologic/orthopedic/dental: treat specific anomalies (strabismus/refractive correction, scoliosis/pectus management, dental care).
• Metabolic: weight/obesity management.
• Pharmacogenomics / advanced therapeutics (gene, cell, RNA, targeted, immuno): none established or in trials specific to this CNV. Oxytocin rescued social deficits in the deletion mouse model (35346312) — hypothesis-generating, not a duplication therapy.
• Genetic counseling: essential given frequent parental inheritance and reduced penetrance.

13. Prevention

• Primary prevention: none possible (constitutional germline CNV). Genetic counseling for recurrence risk (up to ~50% transmission from a carrier parent, though penetrance is reduced) (38421086).
• Reproductive options: prenatal CMA (documented prenatal diagnoses, 33039685) and preimplantation genetic testing for known familial CNV.
• Secondary prevention: early developmental screening and intervention; surveillance for treatable anomalies (cardiac, ocular, seizures).
• Tertiary prevention: multidisciplinary follow-up to limit complications (educational support, epilepsy control, cardiac monitoring).
• Cascade screening of at-risk relatives.
• Immunization / public-health / environmental interventions: not applicable to etiology.

14. Other Species / Natural Disease

• Taxonomy: Homo sapiens (NCBI:txid9606). No naturally occurring 3q29-duplication disease is described in companion animals or wildlife (OMIA: none specific).
• Orthologous genes: the human 3q29 genes have conserved mouse orthologs (Dlg1, Bdh1, Pak2, Fbxo45) enabling engineered models. Evolutionary conservation: synaptic scaffolding (DLG1) and PAK signaling are deeply conserved across vertebrates.
• Comparative biology: the syntenic region has been engineered in mouse (deletion Df/+; 35346312). Zoonotic potential / transmission: not applicable.

15. Model Organisms

• Available models: mouse is the principal system. A 3q29 deletion mouse (Df/+) recapitulates neurodevelopmental/behavioral abnormalities with high construct and face validity and shows reduced hypothalamic oxytocin neurons (35346312). A dedicated duplication (gain-of-dosage) mouse model is, to the best of current literature, lacking — a key gap.
• Model types: engineered chromosomal-region models (deletion); single-gene transgenic/knock-in models of DLG1, PAK2, BDH1 exist in general neuroscience literature and could serve as candidate-gene overexpression models.
• Phenotype recapitulation: deletion Df/+ mice reproduce social/behavioral deficits (face validity) but model the opposite dosage direction to the duplication; caution in interpretation.
• Applications: dissecting synaptic and oxytocinergic mechanisms; testing candidate interventions (e.g., oxytocin, 35346312).
• Resources: MGI (mouse orthologs Dlg1, Bdh1, Pak2, Fbxo45); IMPC/IMSR for single-gene alleles.

Key References (PMID)

• 33039685 — Coyan & Dyer 2020: 11 new cases + literature; second-hit modifiers; prenatal cases.
• 38421086 — Massier et al. 2024: cohort of 46 patients; mild inherited NDD; SRO uncertain.
• 39739615 — Kashevarova et al. 2025: review + BDH1 single-gene critical region; dup vs del comparison; 1:5000.
• 29501613 — Tassano et al. 2018: 448-kb DLG1+BDH1 critical region; heterotopia.
• 24838842 — Fernández-Jaén et al. 2014: severe case; PAK2/DLG1/BDH1/FBXO45 candidates.
• 32874693 — Streata et al. 2020: phenotype heterogeneity; late-onset case.
• 37165454 — Yilmaz et al. 2023: NAHR mechanism, segmental duplications, 21 genes.
• 30263904 — Kessi et al. 2018: overlapping CNV case.
• 25735547 — Guida et al. 2015: proximal 3q29 dup with OAVS.
• 39080272 — Ormond et al. 2024: post-zygotic 3q29 dup in MZ twins.
• 41039406 — 2025: 3q29 dup co-occurring with AMeD (ADH5/ALDH2) syndrome.
• 35346312 — Takemoto et al. 2022: 3q29 deletion mouse; oxytocin rescue.
• 36305444 — Kaba & Çelik 2022: reciprocal 3q29 deletion case (diagnostic/differential context).
• 37691301 — Pollak et al. 2023: 3q29 registry/musculoskeletal (deletion; registry context).
• 24776740 — Szatkiewicz et al. 2014: Swedish schizophrenia CNV study; 3q29 deletion associated with SCZ.
• 22130109 — Grozeva et al. 2012: UK WTCCC CNV frequencies; 3q29 deletion enriched in SCZ.
• 22900207 — Nomura & Takumi 2012: review of CNV-based psychiatric animal models; 3q29 among ASD/SCZ loci.
• Ensembl GRCh37 REST (computational, this analysis): 22 protein-coding genes in chr3:195.70–197.35 Mb.

Limitations & Future Directions

• Evidence is dominated by case reports/small cohorts; frequencies are indicative and ascertainment-biased toward NDD.
• The smallest region of overlap and the true driver gene(s) remain unresolved (BDH1 vs DLG1 debated).
• No duplication-specific animal model, no episignature, and no locus-specific therapy exist.
• Priorities: large genotype–phenotype registries for the duplication, dosage-gain mouse/organoid models, functional dissection of DLG1/BDH1 overexpression, and quantification of penetrance/recurrence risk for counseling.